

Spark Therapeutics, Inc.
Form 8-K
January 07, 2019

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 7, 2019

Spark Therapeutics, Inc.
(Exact Name of Registrant as Specified in its Charter)

Delaware 001-36819 46-2654405
(State or Other Jurisdiction (Commission (IRS Employer
of Incorporation) File Number) Identification No.)

3737 Market Street
Suite 1300 19104
Philadelphia, PA
(Address of Principal Executive Offices) (Zip Code)

Registrant's telephone number, including area code: (888) 772-7560
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Edgar Filing: Spark Therapeutics, Inc. - Form 8-K

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 2.02. Results of Operations and Financial Condition

On January 7, 2019, Spark Therapeutics, Inc. (the “Company”) will be providing financial information, including information about the Company’s estimated cash balance and the number of vials the Company has shipped of its product, LUXURNA® (voretigene neparvovec-rzyl) as of December 31, 2018, in the Company’s presentation at the 2019 J.P. Morgan Healthcare Conference (the “JPMorgan Conference”) and meetings with investors. As of December 31, 2018, the Company’s approximate cash and cash equivalents, restricted cash and marketable securities was \$601 million and the Company had shipped 75 vials of LUXTURNA.

The information in this Item 2.02 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 7.01. Regulation FD Disclosure

As referenced above, the Company will be giving a presentation at the JPMorgan Conference on January 7, 2019. A copy of the presentation, including a slide setting forth certain cautionary language intended to qualify the forward-looking statements included in the presentation, is furnished as Exhibit 99.1 to this Current Report and is incorporated herein by reference.

The information in this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits

Exhibit 99.1 Spark Therapeutics, Inc. Presentation for the 2019 J.P. Morgan Healthcare Conference dated January 7, 2019

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SPARK THERAPEUTICS,
INC.

Date: January 7, 2019 By: /s/ Joseph W. La Barge
Joseph W. La Barge
Chief Legal Officer

Exhibit Index

Exhibit 99.1 Spark Therapeutics, Inc. Presentation for the 2019 J.P. Morgan Healthcare Conference dated January 7, 2019